Jessica Freeman
Psychiatric/Mental Health · Calhoun, GANPI 1023695707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 477 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 27.7% of the total. 2025 is the largest year on record at $2,585, more than ten times the $159 reported in 2022. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$904
- Neurocrine Biosciences, Inc.$638
- Teva Pharmaceuticals USA, Inc.$561
- Supernus Pharmaceuticals, Inc.$509
- Alkermes, Inc.$423
- plus $2K from 16 others
What the payments were for
- Food & beverage$7,13099%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 209 | $2,003 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $904 |
| Neurocrine Biosciences, Inc. | 24 | $638 |
| Teva Pharmaceuticals USA, Inc. | 27 | $561 |
| Supernus Pharmaceuticals, Inc. | 21 | $509 |
| Alkermes, Inc. | 19 | $423 |
| Vanda Pharmaceuticals Inc. | 21 | $309 |
| Lundbeck LLC | 14 | $261 |
| Otsuka America Pharmaceutical, Inc. | 11 | $205 |
| Idorsia Pharmaceuticals US Inc | 11 | $198 |
| Noven Therapeutics, LLC | 11 | $197 |
| Almatica Pharma LLC | 16 | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $168 |
| Axsome Therapeutics, Inc. | 4 | $142 |
| Johnson & Johnson | 6 | $137 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Corium, LLC | 4 | $89 |
| Bausch Health US, LLC | 3 | $63 |
| Tris Pharma Inc | 2 | $44 |
| Indivior Inc. | 1 | $26 |
| Noven Pharmaceuticals, Inc. | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,220 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 21 | $156,331 |
| IngrezzaValbenazine Tosylate | 17 | $145,331 |
| AustedoDeutetrabenazine | 14 | $89,766 |
| VraylarCariprazine Hcl | 34 | $70,546 |
| RexultiBrexpiprazole | 20 | $27,880 |
| AuvelityDextromethorphan Hbr/Bupropion | 19 | $21,232 |
| TrintellixVortioxetine Hydrobromide | 22 | $9,710 |
| Paliperidone ErPaliperidone | 17 | $4,779 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 58 | $2,878 |
| Quetiapine Fumarate | 141 | $2,413 |
| Lurasidone Hcl | 11 | $2,408 |
| Aripiprazole | 35 | $2,106 |
| Oxcarbazepine | 18 | $1,724 |
| Fluphenazine Hcl | 15 | $1,492 |
| Clozapine | 17 | $1,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $561 | $246,09735 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $638 | $145,33117 claims |
| AbbVieVraylar | $2,003 | $70,54634 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $205 | $27,88020 claims |
| Axsome Therapeutics, Inc.Auvelity | $142 | $21,23219 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $168 | $9,71022 claims |
| Almatica Pharma LLCSertraline Hcl | $194 | $23531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Calhoun
- Meridee McArthurCalhoun$8K
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.